MedTrace Logo

Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia

NCT05563818 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2023-09-22

No results posted yet for this study

Summary

Brief Summary:

Definition: A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public.

Limit: 5000 characters. The purpose of this study is to investigate the relationship between speech features and severity of positive and negative clinical symptoms in Arabic speaking patients with schizophrenia. Individuals will be invited to participate in this study because (1) they have a confirmed clinical diagnosis of schizophrenia; (2) they plan to receive routine clinical care for schizophrenia at one of the four participating sites; (3) they speak Arabic as a first language.

Participants must be between the ages of 18-65 years. Participation will involve seven visits consisting of one baseline visit and six monthly follow-up visits. All participants will continue to receive routine clinical care.

Participation in this research will involve providing speech samples using standardized tasks collected using an electronic device. Additionally, study team members will assess positive and negative symptoms of schizophrenia using validated questionnaires.

Conditions

Interventions

OTHER

WinterLight Mobile Phone Speech Analysis

N/A- observational study

Sponsors & Collaborators

  • Winterlight Labs

    collaborator INDUSTRY

  • Hikma Pharmaceuticals LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-09
Primary Completion
2022-12-20
Completion
2022-12-20

Countries

  • Algeria
  • Egypt
  • Jordan
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05563818 on ClinicalTrials.gov